The pending petition for certiorari to the U.S. Supreme Court by Purdue Pharma, regarding its abuse-deterrent opioid formulation patents, could have significant implications for patent law, specifically in how courts evaluate secondary considerations in obviousness analyses. If the Supreme Court agrees to review the case, it could potentially alter the nexus standard originally developed by the U.S. Court of Appeals for the Federal Circuit. Legal professionals anticipate that such a shift might impact how obviousness is assessed in future patent disputes.
For further insights into the ramifications of this case, the possible changes in legal approach, and how practitioners can prepare for potential outcomes, Purdue Pharma’s legal challenge is explored in depth here.